Rho-kinase inhibitors (ROCK inhibitors) represent the newest class of glaucoma medications developed in recent years. The known drug in this group is Netarsudil (Rhopressa).
Innovative Mechanism of Action
Unlike other medications, ROCK inhibitors directly target the site of the disease—the trabecular meshwork. They relax the trabecular cells, reduce tissue stiffness, and thus directly enhance drainage through the eye's main drainage pathway.
Efficacy and Side Effects
The drug is highly effective even in patients with 'normal' or low pressure who still require additional pressure reduction (normal-tension glaucoma). It is taken once daily. The main side effects are prominent eye redness (which sometimes resolves over time) and tiny, harmless deposits on the cornea.